Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung CancerSabine Schmid, Geoffrey Liu, Frances A. Shepherd et al.|Clinical Lung Cancer|2022Cited by 23
Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancerSabine Schmid, Geoffrey Liu, Miguel García-Pardo et al.|Lung Cancer|2022Cited by 11
Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohortY Q Li, Geoffrey Liu, Michael K. Wong et al.|Lung Cancer|2024Cited by 4
P48.05 Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?Miguel García-Pardo, G. Liu, Sussane Schmid et al.|Journal of Thoracic Oncology|2021Cited by 3
Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrenceNiki Esfahanian, Geoffrey Liu, Sze Wah Samuel Chan et al.|Cancer Treatment and Research Communications|2023Cited by 2